DE60215219D1 - Verwendung von darifenacin zur behandlung des harndrangs - Google Patents

Verwendung von darifenacin zur behandlung des harndrangs

Info

Publication number
DE60215219D1
DE60215219D1 DE60215219T DE60215219T DE60215219D1 DE 60215219 D1 DE60215219 D1 DE 60215219D1 DE 60215219 T DE60215219 T DE 60215219T DE 60215219 T DE60215219 T DE 60215219T DE 60215219 D1 DE60215219 D1 DE 60215219D1
Authority
DE
Germany
Prior art keywords
harndrangs
darifenacine
treatment
darifenacin
urgency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215219T
Other languages
English (en)
Other versions
DE60215219T2 (de
Inventor
Enrico Colli
Paul Quinn
Dzelal Serdarevic
Laurence Howard Skillern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis International Pharmaceutical Ltd
Original Assignee
Novartis International Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60215219(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis International Pharmaceutical Ltd filed Critical Novartis International Pharmaceutical Ltd
Application granted granted Critical
Publication of DE60215219D1 publication Critical patent/DE60215219D1/de
Publication of DE60215219T2 publication Critical patent/DE60215219T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Document Processing Apparatus (AREA)
  • Processing Of Meat And Fish (AREA)
  • Inorganic Insulating Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
DE60215219T 2001-12-14 2002-03-05 Verwendung von darifenacin zur behandlung des harndrangs Expired - Lifetime DE60215219T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0129962 2001-12-14
GBGB0129962.7A GB0129962D0 (en) 2001-12-14 2001-12-14 Method of treatment
PCT/IB2002/000664 WO2003051354A1 (en) 2001-12-14 2002-03-05 Method of treatment

Publications (2)

Publication Number Publication Date
DE60215219D1 true DE60215219D1 (de) 2006-11-16
DE60215219T2 DE60215219T2 (de) 2007-10-18

Family

ID=9927643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215219T Expired - Lifetime DE60215219T2 (de) 2001-12-14 2002-03-05 Verwendung von darifenacin zur behandlung des harndrangs

Country Status (28)

Country Link
US (3) US20030130338A1 (de)
EP (1) EP1458376B1 (de)
JP (3) JP2005516925A (de)
KR (1) KR100889086B1 (de)
CN (1) CN100488505C (de)
AT (1) ATE341323T1 (de)
AU (1) AU2002236141B2 (de)
BR (1) BR0214925A (de)
CA (1) CA2469702C (de)
CY (1) CY1105814T1 (de)
CZ (1) CZ301283B6 (de)
DE (1) DE60215219T2 (de)
DK (1) DK1458376T3 (de)
ES (1) ES2276910T3 (de)
GB (1) GB0129962D0 (de)
HK (1) HK1073779A1 (de)
HU (1) HU229908B1 (de)
IL (2) IL162391A0 (de)
MX (1) MXPA04005760A (de)
NO (1) NO20042586L (de)
NZ (1) NZ533421A (de)
PL (1) PL206034B1 (de)
PT (1) PT1458376E (de)
RU (1) RU2321398C2 (de)
SI (1) SI1458376T1 (de)
SK (1) SK287510B6 (de)
WO (1) WO2003051354A1 (de)
ZA (1) ZA200404289B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
ES2603747T3 (es) * 2009-02-04 2017-03-01 Astellas Pharma Inc. Composición farmacéutica para administración oral
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
DK1458376T3 (da) 2007-02-12
JP2013199506A (ja) 2013-10-03
NO20042586L (no) 2004-06-18
EP1458376A1 (de) 2004-09-22
SK287510B6 (sk) 2010-12-07
KR20040066892A (ko) 2004-07-27
US8748476B2 (en) 2014-06-10
HK1073779A1 (en) 2005-10-21
SI1458376T1 (sl) 2007-06-30
MXPA04005760A (es) 2005-03-31
WO2003051354A1 (en) 2003-06-26
RU2321398C2 (ru) 2008-04-10
RU2004121780A (ru) 2005-08-10
US20090162433A1 (en) 2009-06-25
CN1604777A (zh) 2005-04-06
CA2469702C (en) 2010-07-06
CZ2004719A3 (cs) 2005-01-12
HU229908B1 (hu) 2014-12-29
AU2002236141B2 (en) 2007-02-01
IL162391A (en) 2012-04-30
IL162391A0 (en) 2005-11-20
GB0129962D0 (en) 2002-02-06
HUP0402625A2 (hu) 2005-04-28
PL206034B1 (pl) 2010-06-30
CY1105814T1 (el) 2011-02-02
CN100488505C (zh) 2009-05-20
SK2502004A3 (en) 2004-10-05
JP2010024244A (ja) 2010-02-04
US20030130338A1 (en) 2003-07-10
NZ533421A (en) 2007-02-23
CZ301283B6 (cs) 2009-12-30
JP2005516925A (ja) 2005-06-09
ATE341323T1 (de) 2006-10-15
EP1458376B1 (de) 2006-10-04
PL369426A1 (en) 2005-04-18
AU2002236141A1 (en) 2003-06-30
PT1458376E (pt) 2007-01-31
KR100889086B1 (ko) 2009-03-16
DE60215219T2 (de) 2007-10-18
ES2276910T3 (es) 2007-07-01
US20070264333A1 (en) 2007-11-15
CA2469702A1 (en) 2003-06-26
BR0214925A (pt) 2004-12-21
ZA200404289B (en) 2005-09-28

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
ATE369861T1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
HK1073779A1 (en) The use of darifenacin and the salt thereof
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
GB0020504D0 (en) Therapeutic method
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
IL158186A0 (en) Pharmaceutically active compounds and methods of use
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
EP1370697A4 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: SERDAREVIC, DZELAL, SANDWICH, KENT, GB

Inventor name: QUINN, PAUL, SANDWICH, KENT, GB

Inventor name: COLLI, ENRICO, ARCORE, IT

Inventor name: SKILLERN, LAURENCE HOWARD, SANDWICH, KENT, GB

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN